Mosaic ImmunoEngineering Inc. (CPMV) stock
CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.33+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
Mosaic ImmunoEngineering r&d expenses
Research and development expenses are spending on new products and technology.
Mosaic ImmunoEngineering's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.66K, down 27.4% year over year. For fiscal 2025 it was $63.98K, down 65.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.98K | -65.2% |
| FY2024 | Dec 31, 2024 | $183.87K | -57.8% |
| FY2023 | Dec 31, 2023 | $435.45K | -58.5% |
| FY2022 | Dec 31, 2022 | $1.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $15.61K | -2.5% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $15.88K | +0.5% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $16.13K | -0.7% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $16.04K | -59.5% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $16.01K | -73.6% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $15.80K | -76.5% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $16.25K | -67.5% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $39.60K | -53.4% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $60.71K | -50.5% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $67.31K | -62.2% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $49.99K | -75.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $84.93K | -59.8% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $122.64K | -59.5% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $177.90K | -45.7% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $207.02K | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $211.08K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $302.69K | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $327.66K | – |
See a number that looks wrong?